Mouhssin Oufir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mouhssin Oufir has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
Matthias Hamburger
Univ Appl Sci Northwestern Switzerland, Inst Chem & Bioanalyt, Sch Life Sci, Grundenstr 40, CH-4132 Muttenz, Switzerland
10 shared publications- Matthias Hamburger
Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Basel 4056, Switzerland
9 shared publications Jean-François Hausman
Department of Environment and Agro-biotechnologies, Centre de Recherche Public-Gabriel Lippmann, Rue du Brill, 41, L-4422 Belvaux, Luxembourg
8 shared publicationsLucien Hoffmann
Department of Environment and Agro-biotechnologies, Centre de Recherche Public-Gabriel Lippmann, Rue du Brill, 41, L-4422 Belvaux, Luxembourg
8 shared publications- Jenny Renaut
Luxembourg Institute of Science and Technology (LIST), L-4940 Hautcharage, Luxembourg
6 shared publications - Martin Smieško
Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
6 shared publications
Latest Publications
- Open Access
- 6 November 2019
- Published by Elsevier in Phytomedicine
- Vol. 61, 6
Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro
- 6 November 2019
- Published by Elsevier in Phytomedicine
- Vol. 61, 6
Open AccessAbsence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro
- Open Access
- 1 March 2019
- Published by Swiss Chemical Society in Chimia
- Vol. 73 (3) , 206
Piperine Analogs as Modulators of the Central Nervous System
- 1 March 2019
- Published by Swiss Chemical Society in Chimia
- Vol. 73 (3) , 206
Open AccessPiperine Analogs as Modulators of the Central Nervous System
- Open Access
- 18 January 2019
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 19 (1) , 23
Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro
Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy. Especially in Europe, breast cancer patients use herbal products containing mistletoe (Viscum album L.). The oldest and one of the most prescribed conventional drugs for the treatment of estrogen receptor positive breast cancer is tamoxifen. Aside from positive clinical experience with the combination of tamoxifen and mistletoe, little is known about possible herb-drug interactions (HDIs) between the two products. In the present in vitro study, we investigated the effect of standardized commercial mistletoe preparations on the activity of endoxifen, the major active metabolite of tamoxifen. The estrogen receptor positive human breast carcinoma cell line MCF-7 was treated with (E/Z)-endoxifen hydrochloride in the presence and absence of a defined estradiol concentration. Each concentration of the drug was combined with fermented Viscum album L. extracts (VAE) at clinically relevant doses, and proliferation, apoptosis and cell cycle were analyzed. In parallel, possible inhibition of CYP3A4/5 and CYP2D6 was investigated using 50-donor mixed gender pooled human liver microsomes (HLMs). VAE did not inhibit endoxifen induced cytostasis and cytotoxicity. At higher concentrations, VAE showed an additive inhibitory effect. VAE preparations did not cause inhibition of CYP3A4/5 and CYP2D6 catalyzed tamoxifen metabolism. The in vitro results suggest that mistletoe preparations can be used in combination with tamoxifen without the risk of HDIs.
- 18 January 2019
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 19 (1) , 23
Open AccessAbsence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro
Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy. Especially in Europe, breast cancer patients use herbal products containing mistletoe (Viscum album L.). The oldest and one of the most prescribed conventional drugs for the treatment of estrogen receptor positive breast cancer is tamoxifen. Aside from positive clinical experience with the combination of tamoxifen and mistletoe, little is known about possible herb-drug interactions (HDIs) between the two products. In the present in vitro study, we investigated the effect of standardized commercial mistletoe preparations on the activity of endoxifen, the major active metabolite of tamoxifen. The estrogen receptor positive human breast carcinoma cell line MCF-7 was treated with (E/Z)-endoxifen hydrochloride in the presence and absence of a defined estradiol concentration. Each concentration of the drug was combined with fermented Viscum album L. extracts (VAE) at clinically relevant doses, and proliferation, apoptosis and cell cycle were analyzed. In parallel, possible inhibition of CYP3A4/5 and CYP2D6 was investigated using 50-donor mixed gender pooled human liver microsomes (HLMs). VAE did not inhibit endoxifen induced cytostasis and cytotoxicity. At higher concentrations, VAE showed an additive inhibitory effect. VAE preparations did not cause inhibition of CYP3A4/5 and CYP2D6 catalyzed tamoxifen metabolism. The in vitro results suggest that mistletoe preparations can be used in combination with tamoxifen without the risk of HDIs.
- 1 January 2018
- Published by Elsevier in Journal of Chromatography B
- Vol. 1072, 379-389
GABAA receptor activity modulating piperine analogs: In vitro metabolic stability, metabolite identification, CYP450 reaction phenotyping, and protein binding
- 1 January 2018
- Published by Elsevier in Journal of Chromatography B
- Vol. 1072, 379-389
GABAA receptor activity modulating piperine analogs: In vitro metabolic stability, metabolite identification, CYP450 reaction phenotyping, and protein binding
- Open Access
- 1 December 2016
- Published by Elsevier in Fitoterapia
- Vol. 115, 189-197
Pharmacokinetics of dietary kaempferol and its metabolite 4-hydroxyphenylacetic acid in rats
- 1 December 2016
- Published by Elsevier in Fitoterapia
- Vol. 115, 189-197
Open AccessPharmacokinetics of dietary kaempferol and its metabolite 4-hydroxyphenylacetic acid in rats
- Open Access
- 1 September 2016
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 128, 247-252
Development and full validation of an UPLC-MS/MS method for the quantification of the plant-derived alkaloid indirubin in rat plasma
- 1 September 2016
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 128, 247-252
Open AccessDevelopment and full validation of an UPLC-MS/MS method for the quantification of the plant-derived alkaloid indirubin in rat plasma
- 1 September 2016
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 128, 264-274
Validation of UHPLC–MS/MS methods for the determination of kaempferol and its metabolite 4-hydroxyphenyl acetic acid, and application to in vitro blood-brain barrier and intestinal drug permeability studies
- 1 September 2016
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 128, 264-274
Validation of UHPLC–MS/MS methods for the determination of kaempferol and its metabolite 4-hydroxyphenyl acetic acid, and application to in vitro blood-brain barrier and intestinal drug permeability studies
- 15 July 2016
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 82 (13) , 1192-1201
Caco-2 Permeability Studies and In Vitro hERG Liability Assessment of Tryptanthrin and Indolinone
Tryptanthrin and (E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)indolinone (indolinone) were recently isolated from Isatis tinctoria as potent anti-inflammatory and antiallergic alkaloids, and shown to inhibit COX-2, 5-LOX catalyzed leukotriene synthesis, and mast cell degranulation at low µM to nM concentrations. To assess their suitability for oral administration, we screened the compounds in an in vitro intestinal permeability assay using human colonic adenocarcinoma cells. For exact quantification of the compounds, validated UPLC-MS/MS methods were used. Tryptanthrin displayed high permeability (apparent permeability coefficient > 32.0 × 10−6 cm/s) across the cell monolayer. The efflux ratio below 2 (< 1.12) and unchanged apparent permeability coefficient values in the presence of the P-glycoprotein inhibitor verapamil (50 µM) indicated that tryptanthrin was not involved in P-glycoprotein interactions. For indolinone, a low recovery was found in the human colon adenocarcinoma cell assay. High-resolution mass spectrometry pointed to extensive phase II metabolism of indolinone (sulfation and glucuronidation). Possible cardiotoxic liability of the compounds was assessed in vitro by measurement of an inhibitory effect on human ether-a-go-go-related gene tail currents in stably transfected HEK 293 cells using the patch clamp technique. Low human ether-a-go-go-related gene inhibition was found for tryptanthrin (IC50 > 10 µM) and indolinone (IC50 of 24.96 µM). The analysis of compounds using various in silico methods confirmed favorable pharmacokinetic properties, as well as a slight inhibition of the human ether-a-go-go-related gene potassium channel at micromolar concentrations.
- 15 July 2016
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 82 (13) , 1192-1201
Caco-2 Permeability Studies and In Vitro hERG Liability Assessment of Tryptanthrin and Indolinone
Tryptanthrin and (E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)indolinone (indolinone) were recently isolated from Isatis tinctoria as potent anti-inflammatory and antiallergic alkaloids, and shown to inhibit COX-2, 5-LOX catalyzed leukotriene synthesis, and mast cell degranulation at low µM to nM concentrations. To assess their suitability for oral administration, we screened the compounds in an in vitro intestinal permeability assay using human colonic adenocarcinoma cells. For exact quantification of the compounds, validated UPLC-MS/MS methods were used. Tryptanthrin displayed high permeability (apparent permeability coefficient > 32.0 × 10−6 cm/s) across the cell monolayer. The efflux ratio below 2 (< 1.12) and unchanged apparent permeability coefficient values in the presence of the P-glycoprotein inhibitor verapamil (50 µM) indicated that tryptanthrin was not involved in P-glycoprotein interactions. For indolinone, a low recovery was found in the human colon adenocarcinoma cell assay. High-resolution mass spectrometry pointed to extensive phase II metabolism of indolinone (sulfation and glucuronidation). Possible cardiotoxic liability of the compounds was assessed in vitro by measurement of an inhibitory effect on human ether-a-go-go-related gene tail currents in stably transfected HEK 293 cells using the patch clamp technique. Low human ether-a-go-go-related gene inhibition was found for tryptanthrin (IC50 > 10 µM) and indolinone (IC50 of 24.96 µM). The analysis of compounds using various in silico methods confirmed favorable pharmacokinetic properties, as well as a slight inhibition of the human ether-a-go-go-related gene potassium channel at micromolar concentrations.
- 1 June 2016
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 103, 118-126
In vitro blood–brain barrier permeability predictions for GABAA receptor modulating piperine analogs
- 1 June 2016
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 103, 118-126
In vitro blood–brain barrier permeability predictions for GABAA receptor modulating piperine analogs
- 19 April 2016
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 82 (11/12) , 1021-1029
Pharmacokinetics and In Vitro Blood-Brain Barrier Screening of the Plant-Derived Alkaloid Tryptanthrin
The indolo[2,1-b]quinazoline alkaloid tryptanthrin was previously identified as a potent anti-inflammatory compound with a unique pharmacological profile. It is a potent inhibitor of cyclooxygenase-2, 5-lipooxygenase-catalyzed leukotriene synthesis, and nitric oxide production catalyzed by the inducible nitric oxide synthase. To characterize the pharmacokinetic properties of tryptanthrin, we performed a pilot in vivo study in male Sprague-Dawley rats (2 mg/kg bw i. v.). Moreover, the ability of tryptanthrin to cross the blood-brain barrier was evaluated in three in vitro human and animal blood-brain barrier models. Bioanalytical UPLC-MS/MS methods used were validated according to current international guidelines. A half-life of 40.63 ± 6.66 min and a clearance of 1.00 ± 0.36 L/h/kg were found in the in vivo pharmacokinetic study. In vitro data obtained with the two primary animal blood-brain barrier models showed a good correlation with an immortalized human monoculture blood-brain barrier model (hBMEC cell line), and were indicative of a high blood-brain barrier permeation potential of tryptanthrin. These findings were corroborated by the in silico prediction of blood-brain barrier penetration. P-glycoprotein interaction of tryptanthrin was assessed by calculation of the efflux ratio in bidirectional permeability assays. An efflux ratio below 2 indicated that tryptanthrin is not subjected to active efflux. * Dedicated to Prof. Dr. Dr. h. c. mult. Kurt Hostettmann in recognition of his outstanding contribution to natural product research.
- 19 April 2016
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 82 (11/12) , 1021-1029
Pharmacokinetics and In Vitro Blood-Brain Barrier Screening of the Plant-Derived Alkaloid Tryptanthrin
The indolo[2,1-b]quinazoline alkaloid tryptanthrin was previously identified as a potent anti-inflammatory compound with a unique pharmacological profile. It is a potent inhibitor of cyclooxygenase-2, 5-lipooxygenase-catalyzed leukotriene synthesis, and nitric oxide production catalyzed by the inducible nitric oxide synthase. To characterize the pharmacokinetic properties of tryptanthrin, we performed a pilot in vivo study in male Sprague-Dawley rats (2 mg/kg bw i. v.). Moreover, the ability of tryptanthrin to cross the blood-brain barrier was evaluated in three in vitro human and animal blood-brain barrier models. Bioanalytical UPLC-MS/MS methods used were validated according to current international guidelines. A half-life of 40.63 ± 6.66 min and a clearance of 1.00 ± 0.36 L/h/kg were found in the in vivo pharmacokinetic study. In vitro data obtained with the two primary animal blood-brain barrier models showed a good correlation with an immortalized human monoculture blood-brain barrier model (hBMEC cell line), and were indicative of a high blood-brain barrier permeation potential of tryptanthrin. These findings were corroborated by the in silico prediction of blood-brain barrier penetration. P-glycoprotein interaction of tryptanthrin was assessed by calculation of the efflux ratio in bidirectional permeability assays. An efflux ratio below 2 indicated that tryptanthrin is not subjected to active efflux. * Dedicated to Prof. Dr. Dr. h. c. mult. Kurt Hostettmann in recognition of his outstanding contribution to natural product research.